OR WAIT null SECS
April 03, 2021
Intensified and distributed manufacturing approaches create flexible, local capacity.
March 31, 2021
Set to be operational in 2026, the new facility will provide added antigen and filling capacity for Sanofi’s influenza vaccine, increasing its availability in Canada, the United States, and Europe.
March 29, 2021
EMA has approved the manufacturing of drug product for BioNTech’s COVID-19 vaccine, BNT162b2, at BioNTech’s manufacturing site located in Marburg, Germany.
March 22, 2021
The new facility, which is expected to be operational by spring 2025, will feature 8 x 20,000-L bioreactors with the potential to add further 24 x 20,000-L bioreactors based on market demand.
March 17, 2021
The transaction is set to close during the first half of 2021 and is expected to enhance drug substance and drug product capabilities for WuXi.
March 15, 2021
Lonza will provide a manufacturing suite at its facility in Houston, TX, for the clinical and commercial production of AdCOVID, Altimmune’s single-dose intranasal vaccine candidate.
March 10, 2021
The investments are expected to double Thermo Fisher’s manufacturing capacity while creating more than 1500 jobs at 11 manufacturing sites in the Americas, Europe, and Asia.
The expansion plans to increase Vectura’s DPI dosage form development, specifically its unit dose and multi-dose inhalers, and integrated device design and manufacturing for customer programs.
March 09, 2021
The expansion will allow Ashland to focus on clinical study projects and commercialization activities.
March 01, 2021
Currently, the facility manufactures products for oral diabetes treatment and will be expanded to increase capacity for these products.